365 related articles for article (PubMed ID: 24484403)
1. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.
van den Reek JM; van Lüumig PP; Otero ME; Zweegers J; van de Kerkhof PC; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 May; 170(5):1158-65. PubMed ID: 24484403
[TBL] [Abstract][Full Text] [Related]
2. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
van der Schoot LS; van den Reek JMPA; Groenewoud JMM; Otero ME; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Berends MAM; Arnold WP; Peters B; Andriessen MPM; Den Hengst CW; Kuijpers ALA; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1913-1920. PubMed ID: 31177583
[TBL] [Abstract][Full Text] [Related]
3. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
5. Satisfaction with treatment among patients with psoriasis: a web-based survey study.
van Cranenburgh OD; de Korte J; Sprangers MA; de Rie MA; Smets EM
Br J Dermatol; 2013 Aug; 169(2):398-405. PubMed ID: 23565643
[TBL] [Abstract][Full Text] [Related]
6. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
[TBL] [Abstract][Full Text] [Related]
7. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
10. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities.
Ichiyama S; Ito M; Funasaka Y; Abe M; Nishida E; Muramatsu S; Nishihara H; Kato H; Morita A; Imafuku S; Saeki H
J Dermatol; 2018 Jun; 45(6):727-731. PubMed ID: 29356075
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
12. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
13. Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; Kievit W; de Jong EM
Br J Dermatol; 2014 Nov; 171(5):1091-8. PubMed ID: 24861358
[TBL] [Abstract][Full Text] [Related]
14. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
15. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity.
Vaidya TS; Anderson KL; Feldman SR
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437293
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
18. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
[TBL] [Abstract][Full Text] [Related]
19. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.
Menting SP; Sitaram AS; Bonnerjee-van der Stok HM; de Rie MA; Hooft L; Spuls PI
Br J Dermatol; 2014 Oct; 171(4):875-83. PubMed ID: 24673245
[TBL] [Abstract][Full Text] [Related]
20. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]